J Cancer 2019; 10(18):4278-4285. doi:10.7150/jca.31859

Research Paper

GnRHa for Ovarian Protection and the Association between AMH and Ovarian Function during Adjuvant Chemotherapy for Breast Cancer

Ying Zhong1, Yan Lin1, Xinqi Cheng2, Xin Huang1, Yidong Zhou1, Feng Mao1, Yajing Wang2, Jinghong Guan1, Songjie Shen1, Yali Xu1, Li Peng1, Yan li1, Xi Cao1, Qiang Sun1✉

1. Department of Breast Disease, Peking Union Medical College Hospital, Shuaifuyuan, Wangfujing, Beijing 100730, China
2. Department of Clinical laboratory, Peking Union Medical College Hospital, Shuaifuyuan, Wangfujing, Beijing 100730, China.

Abstract

Background: Chemotherapy impairs ovarian function in premenopausal breast cancer patients. Many breast cancer patients experience menopause earlier and therefore lose their reproductive abilities. The protective effect of gonadotropin-releasing hormone agonist (GnRha) upon the ovary is clearly apparent for hormone receptor (HR) negative patients, although the available data is not consistent for the patient body as a whole when considered regardless of HR status. It is also unknown whether levels of Anti-Mullerian Hormone (AMH) can reflect the influence of chemotherapy upon the ovary.

Methods: We randomly assigned 98 premenopausal breast cancer patients regardless HR-positive or -negative to receive either standard chemotherapy with GnRHa (GnRHa group) or standard chemotherapy without GnRHa (control group). Our primary end point was ovarian failure rate (OVF) at 1 year. In addition, we observed the change of AMH level during chemotherapy and the association between AMH and OVF.

Results: OVF was significantly lower (44.7%) in the GnRHa group than in the control group (80.6%; P=0.002). Median AMH levels were significantly higher before chemotherapy when compared to after 1/2cycles of chemotherapy, both in the GnRHa group (1.86ng/ml vs 0.12ng/ml; P=0.000) and in the control group (1.57ng/ml vs 0.10ng/ml; P=0.000). OVF was 91.3% in the AMH baseline level <1.1ng/ml group and 63.5% in the AMH baseline level >1.1ng/ml group (P=0.013).

Conclusion: Data showed that GnRHa may have a protective effect on young breast cancer patients regardless of HR during chemotherapy. AMH could reflect changes of OVF during chemotherapy and predict OVF after chemotherapy.

Keywords: Breast cancer, Chemotherapy, Ovarian function, GnRH agonist, AMH

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
How to cite this article:
Zhong Y, Lin Y, Cheng X, Huang X, Zhou Y, Mao F, Wang Y, Guan J, Shen S, Xu Y, Peng L, li Y, Cao X, Sun Q. GnRHa for Ovarian Protection and the Association between AMH and Ovarian Function during Adjuvant Chemotherapy for Breast Cancer. J Cancer 2019; 10(18):4278-4285. doi:10.7150/jca.31859. Available from http://www.jcancer.org/v10p4278.htm